Application of the QbD-based approach in the early development of liposomes for nasal administration

Edina Pallagi, Orsolya Jójárt-Laczkovich, Zsófia Németh, P. Szabó-Révész, Ildikó Csóka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In this study, authors adapt the Quality by Design (QbD) concept as well as the Risk Assessment (RA) method to the early development phase of a new nano-sized liposomal formulation for nasal administration with brain target. As a model active agent, a BCS II class drug was chosen to investigate the behaviour of the drugs with lipophilic character. This research presents how to apply this risk-focused approach and concentrates on the first four stages of the QbD implementation. In this way the quality target product profile was defined, the critical factors were identified and an RA was performed. The RA results helped in the factorial design-based liposome preparation by the lipid film hydration method. The prepared liposomes were evaluated (vesicle size, size distribution, and specific surface area). The surface characteristics were also investigated to verify the exactness of the RA and critical factors based theoretical prediction. The results confirm that the QbD approach in liposome development can improve the formulation process. The RA focused predictive approach resulted in a decreased number of studies in practice but in an effective product preparation. Using such innovative design and development models can help to optimise and rationalise the development of liposomes.

Original languageEnglish
Pages (from-to)11-22
Number of pages12
JournalInternational Journal of Pharmaceutics
Volume562
DOIs
Publication statusPublished - May 1 2019

Fingerprint

Intranasal Administration
Liposomes
Pharmaceutical Preparations
Lipids
Brain
Research

Keywords

  • Lipophilic drug containing liposome
  • Liposome
  • Nanocarriers
  • Nasal administration
  • Quality by Design
  • Risk assessment
  • Risk-based formulation

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Application of the QbD-based approach in the early development of liposomes for nasal administration. / Pallagi, Edina; Jójárt-Laczkovich, Orsolya; Németh, Zsófia; Szabó-Révész, P.; Csóka, Ildikó.

In: International Journal of Pharmaceutics, Vol. 562, 01.05.2019, p. 11-22.

Research output: Contribution to journalArticle

Pallagi, Edina ; Jójárt-Laczkovich, Orsolya ; Németh, Zsófia ; Szabó-Révész, P. ; Csóka, Ildikó. / Application of the QbD-based approach in the early development of liposomes for nasal administration. In: International Journal of Pharmaceutics. 2019 ; Vol. 562. pp. 11-22.
@article{675b44b9fbe24af2a19e1c7d18efdbf1,
title = "Application of the QbD-based approach in the early development of liposomes for nasal administration",
abstract = "In this study, authors adapt the Quality by Design (QbD) concept as well as the Risk Assessment (RA) method to the early development phase of a new nano-sized liposomal formulation for nasal administration with brain target. As a model active agent, a BCS II class drug was chosen to investigate the behaviour of the drugs with lipophilic character. This research presents how to apply this risk-focused approach and concentrates on the first four stages of the QbD implementation. In this way the quality target product profile was defined, the critical factors were identified and an RA was performed. The RA results helped in the factorial design-based liposome preparation by the lipid film hydration method. The prepared liposomes were evaluated (vesicle size, size distribution, and specific surface area). The surface characteristics were also investigated to verify the exactness of the RA and critical factors based theoretical prediction. The results confirm that the QbD approach in liposome development can improve the formulation process. The RA focused predictive approach resulted in a decreased number of studies in practice but in an effective product preparation. Using such innovative design and development models can help to optimise and rationalise the development of liposomes.",
keywords = "Lipophilic drug containing liposome, Liposome, Nanocarriers, Nasal administration, Quality by Design, Risk assessment, Risk-based formulation",
author = "Edina Pallagi and Orsolya J{\'o}j{\'a}rt-Laczkovich and Zs{\'o}fia N{\'e}meth and P. Szab{\'o}-R{\'e}v{\'e}sz and Ildik{\'o} Cs{\'o}ka",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.ijpharm.2019.03.021",
language = "English",
volume = "562",
pages = "11--22",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

TY - JOUR

T1 - Application of the QbD-based approach in the early development of liposomes for nasal administration

AU - Pallagi, Edina

AU - Jójárt-Laczkovich, Orsolya

AU - Németh, Zsófia

AU - Szabó-Révész, P.

AU - Csóka, Ildikó

PY - 2019/5/1

Y1 - 2019/5/1

N2 - In this study, authors adapt the Quality by Design (QbD) concept as well as the Risk Assessment (RA) method to the early development phase of a new nano-sized liposomal formulation for nasal administration with brain target. As a model active agent, a BCS II class drug was chosen to investigate the behaviour of the drugs with lipophilic character. This research presents how to apply this risk-focused approach and concentrates on the first four stages of the QbD implementation. In this way the quality target product profile was defined, the critical factors were identified and an RA was performed. The RA results helped in the factorial design-based liposome preparation by the lipid film hydration method. The prepared liposomes were evaluated (vesicle size, size distribution, and specific surface area). The surface characteristics were also investigated to verify the exactness of the RA and critical factors based theoretical prediction. The results confirm that the QbD approach in liposome development can improve the formulation process. The RA focused predictive approach resulted in a decreased number of studies in practice but in an effective product preparation. Using such innovative design and development models can help to optimise and rationalise the development of liposomes.

AB - In this study, authors adapt the Quality by Design (QbD) concept as well as the Risk Assessment (RA) method to the early development phase of a new nano-sized liposomal formulation for nasal administration with brain target. As a model active agent, a BCS II class drug was chosen to investigate the behaviour of the drugs with lipophilic character. This research presents how to apply this risk-focused approach and concentrates on the first four stages of the QbD implementation. In this way the quality target product profile was defined, the critical factors were identified and an RA was performed. The RA results helped in the factorial design-based liposome preparation by the lipid film hydration method. The prepared liposomes were evaluated (vesicle size, size distribution, and specific surface area). The surface characteristics were also investigated to verify the exactness of the RA and critical factors based theoretical prediction. The results confirm that the QbD approach in liposome development can improve the formulation process. The RA focused predictive approach resulted in a decreased number of studies in practice but in an effective product preparation. Using such innovative design and development models can help to optimise and rationalise the development of liposomes.

KW - Lipophilic drug containing liposome

KW - Liposome

KW - Nanocarriers

KW - Nasal administration

KW - Quality by Design

KW - Risk assessment

KW - Risk-based formulation

UR - http://www.scopus.com/inward/record.url?scp=85062963449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062963449&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2019.03.021

DO - 10.1016/j.ijpharm.2019.03.021

M3 - Article

VL - 562

SP - 11

EP - 22

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

ER -